Univariate analysis | Multivariate analysisa | |||||
---|---|---|---|---|---|---|
HR | 95% CI | P value | HR | 95% CI | P value | |
CKD progression | ||||||
Model 1 | ||||||
ACR < 30 | 1 | Ref. | 1 | Ref. | ||
ACR ≥ 30 | 4.22 | 1.76–10.11 | 0.001 | 3.43 | 1.34–8.76 | 0.010 |
Model 2 | ||||||
NAPCR < 120 | 1 | Ref. | 1 | Ref. | ||
NAPCR ≥ 120 | 7.59 | 2.60–22.15 | <0.001 | 6.84 | 2.25–20.85 | 0.001 |
Model 3 | ||||||
ACR < 30; NAPCR < 120 | 1 | Ref. | 1 | Ref. | ||
ACR < 30; NAPCR ≥ 120 | 18.88 | 2.27–157.05 | 0.007 | 21.82 | 2.57–185.62 | 0.005 |
ACR ≥ 30; NAPCR < 120 | 11.90 | 1.23–114.79 | 0.032 | 11.62 | 1.19–113.97 | 0.035 |
ACR ≥ 30; NAPCR ≥ 120 | 27.27 | 3.60–206.66 | 0.001 | 21.40 | 2.70–169.78 | 0.004 |
Accelerated eGFR decline | ||||||
Model 1 | ||||||
ACR < 30 | 1 | Ref. | 1 | Ref. | ||
ACR ≥ 30 | 1.72 | 1.08–02.76 | 0.024 | 1.55 | 0.92–2.61 | 0.100 |
Model 2 | ||||||
NAPCR < 120 | 1 | Ref. | 1 | Ref. | ||
NAPCR ≥ 120 | 2.01 | 1.25–3.24 | 0.004 | 1.95 | 1.16–3.26 | 0.011 |
Model 3 | ||||||
ACR < 30; NAPCR < 120 | 1 | Ref. | 1 | Ref. | ||
ACR < 30; NAPCR ≥ 120 | 1.64 | 0.81–3.31 | 0.170 | 1.66 | 0.81–3.43 | 0.169 |
ACR ≥ 30; NAPCR < 120 | 1.21 | 0.52–2.84 | 0.659 | 1.12 | 0.47–2.70 | 0.800 |
ACR ≥ 30; NAPCR ≥ 120 | 2.39 | 1.36–4.17 | 0.002 | 2.28 | 1.21–4.29 | 0.011 |